Clinical Trials for Non-Small Cell Lung Cancer

Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT5528 in Patients With Advanced Malignancies Associated With EphA2 Expression

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial involves patients over 18 with advanced solid tumors expressing high levels of EphA2, testing the safety and efficacy of BT5528, a targeted Bicycle Toxin Conjugate linked to MMAE, as a monotherapy and in combination with the PD-1 inhibitor nivolumab, particularly in ovarian, urothelial, lung, breast, head and neck, and gastric cancers after progression on standard treatments.

ClinicalTrials.gov ID: NCT04180371

A Randomized Phase II Study of Tepotinib With or Without Ramucirumab in Participants With MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP SUB-STUDY)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial targets patients with Stage IV or recurrent non-small cell lung cancer characterized by MET exon 14 skipping mutation, evaluating the efficacy of tepotinib, a MET kinase inhibitor, with or without ramucirumab, a monoclonal antibody that inhibits angiogenesis. Eligible patients must have progressed after prior treatment, with the study aiming to compare response rates and other survival outcomes.

ClinicalTrials.gov ID: NCT06031688

Grid Radiotherapy for Advanced Non-Small Cell Lung Cancer At the Time of Progression on Immune Checkpoint Inhibition

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial is for adult patients with stage IV non-small cell lung cancer that has progressed on immune checkpoint inhibitors, assessing the combination of grid radiotherapy, which delivers high doses to specific tumor regions, with ongoing standard immunotherapy to potentially enhance tumor response and outcomes.

ClinicalTrials.gov ID: NCT06660407

Phase II Study of Dose Attenuated Chemotherapy in Patients With Lung Cancer and Age > 70 and/or Comorbidities

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This study evaluates dose-adjusted chemotherapy regimens in lung cancer patients over 70 or with comorbidities, using treatments like platinum doublets and single-agent chemotherapy with options for immunotherapy or VEGF inhibitors, to maintain efficacy and minimize adverse effects. Eligible participants include those with stage IV or certain stage III lung cancer, ECOG performance status of 0-3, and measurable disease.

ClinicalTrials.gov ID: NCT05800587

A Phase Ib Multicenter, Open-label Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Immunotherapy Agents With and Without Chemotherapy Agents in First-line Treatment of Patients With Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor 2 (HER2) Overexpression (OE) (DESTINY-Lung03)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial evaluates the safety and tolerability of trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate targeting HER2, in combination with immunotherapy agents (durvalumab, volrustomig, and rilvegostomig) and chemotherapy agents (cisplatin, carboplatin, pemetrexed) as a first-line treatment in patients with advanced or metastatic non-squamous NSCLC with HER2 overexpression. Eligible patients are those with unresectable or metastatic disease and an ECOG performance status of 0 or 1, who have not received prior treatment for their advanced condition.

ClinicalTrials.gov ID: NCT04686305

A Phase 1b/2, Open-label, Randomized Study of Vudalimab in Combination With Chemotherapy or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced Non-small Cell Lung Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial involves patients with advanced nonsquamous non-small cell lung cancer who have not received prior systemic treatment and evaluates vudalimab, a bispecific antibody targeting PD-1 and CTLA-4, in combination with chemotherapy versus pembrolizumab plus chemotherapy for efficacy and safety.

ClinicalTrials.gov ID: NCT06173505

A Phase 1, Open-Label, Dose Escalation of HBI-2376 in Patients With Advanced Malignant Solid Tumors Harboring KRAS or EGFR Mutations

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial focuses on patients with advanced solid tumors carrying KRAS or EGFR mutations who have relapsed or are refractory to standard treatments, using the oral SHP2 inhibitor HBI-2376 to target pathways involved in cancer cell survival and proliferation.

ClinicalTrials.gov ID: NCT05163028

A First-In-human Phase I, Non-randomized, Open-label, Multi-center Dose Escalation Trial of BI 764532 Administered by Parenteral Route in Patients With Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: The trial involves adults with DLL3-positive small cell lung carcinoma and neuroendocrine carcinomas, including those with brain metastases under specific conditions, who have exhausted standard therapies. The investigational treatment, BI 764532, is a bispecific antibody designed to engage T-cells by linking DLL3 on cancer cells with CD3 on T-cells, aiming to determine its maximum tolerated dose and evaluate its safety and anti-tumor activity.

ClinicalTrials.gov ID: NCT04429087

A Phase 2 Trial of Combination Therapies With Adagrasib in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial targets patients with advanced, untreated, unresectable, or metastatic non-small cell lung cancer with the KRAS G12C mutation, including both squamous and non-squamous histology, and involves treatment with a combination of adagrasib, a KRAS G12C inhibitor, pembrolizumab, and standard chemotherapy agents.

ClinicalTrials.gov ID: NCT05609578

A Phase IIIb, Randomized, Multicenter, Open-label Study to Assess the Efficacy of Durvalumab Plus Tremelimumab Versus Pembrolizumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients With Non-Squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON).

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: The trial investigates the efficacy of durvalumab and tremelimumab combined with platinum-based chemotherapy compared to pembrolizumab with similar chemotherapy for first-line treatment in stage IV metastatic non-squamous NSCLC patients with STK11, KEAP1, or KRAS mutations. Durvalumab and tremelimumab are monoclonal antibodies that target the PD-L1 and CTLA-4 pathways, respectively.

ClinicalTrials.gov ID: NCT06008093